If You Like Your Emergency, You Can Keep Your Emergency
May 5, 2023 15:57:06 GMT
c2crusher likes this
Post by icemandios on May 5, 2023 15:57:06 GMT
Despite the Biden Admin declaring the pandemic is over on May 11, and despite the WHO declaring it is over as of today......
Our intrepid FDA is still granting EUA's for COVID tests, and strangely, entities are still seeking them:
FDA Issues EUAs for COVID Molecular Tests From Access Medical, Drexel University
May 05, 2023 | staff reporter
NEW YORK – Access Medical Laboratories and Drexel University College of Medicine each recently were issued Emergency Use Authorizations by the US Food and Drug Administration for COVID-19 molecular diagnostic tests to detect the SARS-CoV-2 virus.
The agency granted Access Medical an EUA on Wednesday for its Global Direct RT-PCR Test for the qualitative detection of SARS-CoV-2 nucleic acid in nasopharyngeal and anterior nasal swab specimens. The use of the test is limited to the company's CLIA-certified laboratory in Jupiter, Florida.
Meantime, the FDA granted EUA to Drexel's SARS-CoV-2 DUCoM-PDL Modified Tetracore Assay last week for the qualitative detection of SARS-CoV-2 nucleic acid in mid-turbinate nasal swab specimens. The test can be performed only at Drexel's CLIA-certified lab in Philadelphia.
According to the FDA, for both tests, nucleic acid is extracted, isolated, and purified then reverse transcribed into cDNA for PCR amplification followed by detection with an RT-PCR instrument.
May 05, 2023 | staff reporter
NEW YORK – Access Medical Laboratories and Drexel University College of Medicine each recently were issued Emergency Use Authorizations by the US Food and Drug Administration for COVID-19 molecular diagnostic tests to detect the SARS-CoV-2 virus.
The agency granted Access Medical an EUA on Wednesday for its Global Direct RT-PCR Test for the qualitative detection of SARS-CoV-2 nucleic acid in nasopharyngeal and anterior nasal swab specimens. The use of the test is limited to the company's CLIA-certified laboratory in Jupiter, Florida.
Meantime, the FDA granted EUA to Drexel's SARS-CoV-2 DUCoM-PDL Modified Tetracore Assay last week for the qualitative detection of SARS-CoV-2 nucleic acid in mid-turbinate nasal swab specimens. The test can be performed only at Drexel's CLIA-certified lab in Philadelphia.
According to the FDA, for both tests, nucleic acid is extracted, isolated, and purified then reverse transcribed into cDNA for PCR amplification followed by detection with an RT-PCR instrument.